BioSpace News Archive

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on December 14, 2022.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors.

Vincerx Pharma, Inc. (Nasdaq: VINC) today announced two poster presentations of preclinical and clinical data on the Company’s lead asset, enitociclib (also known as VIP152) at the 64th American Society of Hematology (ASH) Annual Meeting 2022 and additional data-related updates in the enitociclib program.

A new study by researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, reveals that people with neuroendocrine cancer overwhelmingly prioritize quality of life over living longer.

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF) today announced that Payton Nyquvest, Founder and CEO of Numinus, will present at the KCSA Mental Health Investor Conference to be held at VirtualInvestorConferences.com on Thursday, December 15, 2022 at 12:30 p.m. ET / 9:30 a.m. PT.

Magenta Therapeutics (Nasdaq: MGTA) highlights updated clinical data from the ongoing MGTA-117 Phase 1/2 dose-escalation clinical trial made in an oral presentation today at the American Society of Hematology 2022 Annual (ASH) Meeting in New Orleans and provides program updates across the portfolio.

Toronto, Ontario--(Newsfile Corp. - December 12, 2022) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the “Company” or “Aires”) is pleased to announce that, further to its press release of December 6, 2022, Mr. Vitali Savitski has been appointed as Chief Financial Officer effective immediately.

Servier announced findings from a retrospective study observing higher overall survival in adolescent and young adult newly-diagnosed acute lymphoblastic leukemia patients treated with asparaginase containing pediatric-inspired regimens versus non-pediatric-inspired regimens.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today presented additional positive clinical data from its Phase 1 clinical trial of NX-2127 in two oral sessions by Anthony Mato, M.D., MSCE, former director of the Chronic Lymphocytic (CLL) Program at Memorial Sloan Kettering Cancer Center, and Omar Abdel-Wahab, M.D., Chair of Sloan Kettering Institute (SKI) Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the first quarter ended October 31, 2022 of Fiscal Year 2023 (Q1 FY23) and provided a business update on recent corporate and operational developments.